Loading
An Iranian maker of biological medicines, including copies of cancer antibodies, whose own pertuzumab copy matched the original in a phase 3 breast cancer trial.
CinnaGen describes itself as a biopharmaceutical company with a head office in Shahrak-e Gharb, Tehran, and a manufacturing site in the Simin Dasht industrial area of Karaj, with product lines including oncology and haematology and pages on biosimilars and clinical trials. Its site, read from an Internet Archive copy of 30 September 2026, lists AryoGen among its family of companies.
It sponsored the phase 3 equivalence trial of P013, its proposed pertuzumab biosimilar (NCT04957212, also registered in the Iranian Registry of Clinical Trials as IRCT20150303021315N11), in which 214 women with HER2-positive breast cancer were randomised to P013 or the originator Perjeta with trastuzumab, carboplatin and docetaxel before surgery; breast pathological complete response was 67.62% against 71.57%, within the equivalence margin. cinnagen.com did not answer from here on 4 November 2026.
A second HER2 antibody that binds a different spot from trastuzumab, blocking HER2 from pairing with HER3; together they extended survival by 16 months in CLEOPATRA.
Shares AryoGen Pharmed, Biosimilar manufacturing and comparability, Biosimilar, HER2-positive breast cancer.
Shares AryoGen Pharmed, Biosimilar manufacturing and comparability, Biosimilar.
Shares AryoGen Pharmed, Biosimilar, HER2-positive breast cancer.
Shares AryoGen Pharmed, Biosimilar.
Shares Biosimilar manufacturing and comparability, Biosimilar, HER2-positive breast cancer.
Shares Pertuzumab, HER2-positive breast cancer.
Shares Biosimilar manufacturing and comparability, Biosimilar.
Shares Pertuzumab, HER2-positive breast cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/